Issue

Vol. 13 (2021)

Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope

https://doi.org/10.1007/s40820-020-00560-9
Xinyu Lou
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, People’s Republic of China
Zhichao Chen
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, People’s Republic of China
Zhonggui He
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, People’s Republic of China
Mengchi Sun
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, People’s Republic of China
Jin Sun
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, People’s Republic of China

Corresponding Author: Jin Sun

sunjin@syphu.edu.cn

Nano-Micro Letters, Vol. 13 (2021), Article Number: 37

Abstract

The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: “humans are nearing the first commercial live bacteria therapeutic.” However, the facultative anaerobe Salmonella typhimurium VNP20009, which is particularly safe and shows anticancer effects in preclinical studies, had failed in a phase I clinical trial due to low tumor regression and undesired dose-dependent side effects. This is almost certain to disappoint people’s inflated expectations, but it is noted that recent state-of-the-art research has turned attention to bacteria-mediated synergistic cancer therapy (BMSCT). In this review, the foundation of bacteria-mediated bio-therapy is outlined. Then, we summarize the potential benefits and challenges of bacterial bio-therapy in combination with different traditional anticancer therapeutic modalities (chemotherapy, photothermal therapy, reactive oxygen and nitrogen species therapy, immunotherapy, or prodrug-activating therapy) in the past 5 years. Next, we discuss multiple administration routes of BMSCT, highlighting potentiated antitumor responses and avoidance of potential side effects. Finally, we envision the opportunities and challenges for BMSCT development, with the purpose of inspiring medicinal scientists to widely utilize the microbiome approach in patient populations.


Highlights:


1 Introducing mechanisms of antitumor activation produced by bacteria-mediated bio-therapy in detail.
2 Comprehensively reviewing multiple administration routes of bacterial bio-therapy in combination with different traditional anticancer therapeutic modalities over the recent 5 years.
3 Discussing the potential benefits and challenges of this anticancer approach, and conveying the development tendency and the application prospect of this field.

Keywords

Bacteria-mediated synergistic cancer therapy Multiple administration routes Antitumor responses Potential side effects Microbiome approach
Lou, Xinyu, Zhichao Chen, Zhonggui He, Mengchi Sun, and Jin Sun. 2021. “Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope”. Nano-Micro Letters 13 (January):37. https://doi.org/10.1007/s40820-020-00560-9.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, L. Torre et al., Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). https://doi.org/10.3322/caac.21492
  2. S. Felgner, V. Pawar, D. Kocijancic, M. Erhardt, S. Weiss, Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. Microb. Biotechnol. 10, 1074–1078 (2017). https://doi.org/10.1111/1751-7915.12787
  3. B. Sun, C. Luo, H. Yu, X. Zhang, Q. Chen et al., Disulfide bond-driven oxidation- and reduction-responsive prodrug nanoassemblies for cancer therapy. Nano Lett. 18, 3643–3650 (2018). https://doi.org/10.1021/acs.nanolett.8b00737
  4. R. Wijdeven, B. Pang, Y. Assaraf, J. Neefjes, Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics. Drug Resist. Updat. 28, 65–81 (2016). https://doi.org/10.1016/j.drup.2016.07.001
  5. S. Cann, J. Van Netten, C. Netten, Dr William Coley and tumour regression: a place in history or in the future. Postgrad. Med. J. 79, 672–680 (2004). https://doi.org/10.1111/j.1526-4637.2003.03051.x
  6. W.B. Coley, The treatment of sarcoma of the long bones. Ann. Surg. 97, 434–460 (1933). https://doi.org/10.1097/00000658-193303000-00010
  7. W. Song, A.C. Anselmo, L. Huang, Nanotechnology intervention of the microbiome for cancer therapy. Nat. Nanotechnol. 14, 1093–1103 (2019). https://doi.org/10.1038/s41565-019-0589-5
  8. S. Zhou, C. Gravekamp, D. Bermudes, K. Liu, Tumour-targeting bacteria engineered to fight cancer. Nat. Rev. Cancer 18, 727–743 (2018). https://doi.org/10.1038/s41568-018-0070-z
  9. H. Nishikawa, E. Sato, G. Briones, L.M. Chen, M. Matsuo et al., In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Investig. 116, 1946–1954 (2006). https://doi.org/10.1172/jci28045
  10. L. He, H. Yang, J. Tang, Z. Liu, Y. Chen et al., Intestinal probiotics Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. J. Biol. Eng. 13, 58 (2019). https://doi.org/10.1186/s13036-019-0189-9
  11. M. Jimenez, R. Langer, G. Traverso, Microbial therapeutics: new opportunities for drug delivery. J. Exp. Med. 216, 1005–1009 (2019). https://doi.org/10.1084/jem.20190609
  12. Y. Zhang, N. Zhang, M. Zhao, R. Hoffman, Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice. Oncotarget 6, 14625–14631 (2015). https://doi.org/10.18632/oncotarget.3342
  13. C. Lee, C. Wu, A. Shiau, Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int. J. Cancer 122, 930–935 (2008). https://doi.org/10.1002/ijc.23047
  14. L. Leschner, K. Westphal, N. Dietrich, N. Viegas, J. Jablonska et al., Tumor invasion of Salmonella enterica serovar typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS ONE 4, e6692 (2009). https://doi.org/10.1371/journal.pone.0006692
  15. R. Garza-Morales, B. Rendon, M. Malik, J. Garza-Cabrales, A. Aucouturier et al., Lactococcus lactis-targeting melanoma hypoxia with the food-grade lactic acid bacterium. Cancers 12, 438 (2020). https://doi.org/10.3390/cancers12020438
  16. R.W. Kasinskas, N.S. Forbes, Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res. 67, 3201–3209 (2007). https://doi.org/10.1158/0008-5472.Can-06-2618
  17. J.M. Pawelek, K.B. Low, D. Bermudes, Tumor-targeted salmonella as a novel anticancer vector. Cancer Res. 57, 4537–4544 (1997). https://doi.org/10.4067/S0717-95532002000100005
  18. A. Bolhassani, N. Naderi, S. Soleymani, Prospects and progress of listeria-based cancer vaccines. Expert Opin. Biol. Ther. 17, 1389–1400 (2017). https://doi.org/10.1080/14712598.2017.1366446
  19. V.M. Kim, A.B. Blair, P. Lauer, K. Foley, X. Che et al., Anti-pancreatic tumor efficacy of a listeria-based, annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. J. Immunother. Cancer 7, 132 (2019). https://doi.org/10.1186/s40425-019-0601-5
  20. B. Beutler, A. Cerami, The biology of cachectin/TNF—a primary mediator of the host response. Annu. Rev. Immunol. 7, 625–655 (1989). https://doi.org/10.1146/annurev.iy.07.040189.003205
  21. J.E. Kim, T.X. Phan, V.H. Nguyen, H.V. Dinh-Vu, J.H. Zheng et al., Salmonella typhimurium suppresses tumor growth via the pro-inflammatory cytokine interleukin-1β. Theranostics 5, 1328–1342 (2015). https://doi.org/10.7150/thno.11432
  22. T. Phan, V. Nguyen, M. Duong, Y. Hong, H. Choy et al., Activation of inflammasome by attenuated Salmonella typhimurium in bacteria-mediated cancer therapy. Microbiol. Immunol. 59, 664–675 (2015). https://doi.org/10.1111/1348-0421.12333
  23. F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico et al., Cancer immunotherapy based on killing of salmonella-infected tumor cells. Cancer Res. 65, 3920–3927 (2005). https://doi.org/10.1158/0008-5472.Can-04-3002
  24. L. Sfondrini, A. Rossini, D. Besusso, A. Merlo, E. Tagliabue et al., Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 176, 6624–6630 (2006). https://doi.org/10.4049/jimmunol.176.11.6624
  25. F. Coll, E. Harrison, M. Toleman, S. Reuter, K. Raven et al., Longitudinal genomic surveillance of MRSA in the UK reveals transmission patterns in hospitals and the community. Sci. Transl. Med. 9, eaak9745 (2017). https://doi.org/10.1126/scitranslmed.aak9745
  26. W.W. Chang, C.H. Lai, M.C. Chen, C.F. Liu, Y.D. Kuan et al., Salmonella enhance chemosensitivity in tumor through connexin 43 upregulation. Int. J. Cancer 133, 1926–1935 (2013). https://doi.org/10.1002/ijc.28155
  27. D. Chandra, A. Jahangir, W. Quispe-Tintaya, M. Einstein, C. Gravekamp, Myeloid-derived suppressor cells have a central role in attenuated listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br. J. Cancer 108, 2281–2290 (2013). https://doi.org/10.1038/bjc.2013.206
  28. Q. Hu, M. Wu, C. Fang, C. Cheng, M. Zhao et al., Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 15, 2732–2739 (2015). https://doi.org/10.1021/acs.nanolett.5b00570
  29. N.S. Forbes, Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10, 785–794 (2010). https://doi.org/10.1038/nrc2934
  30. A. Bhatt, M. Redinbo, S. Bultman, The role of the microbiome in cancer development and therapy. CA Cancer J. Clin. 67, 326–344 (2017). https://doi.org/10.3322/caac.21398
  31. S. Chowdhury, S. Castro, C. Coker, T. Hinchliffe, N. Arpaia et al., Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat. Med. 25, 1057–1063 (2019). https://doi.org/10.1038/s41591-019-0498-z
  32. S. Picardo, B. Coburn, A. Hansen, The microbiome and cancer for clinicians. Crit. Rev. Oncol. Hematol. 141, 1–12 (2019). https://doi.org/10.1016/j.critrevonc.2019.06.004
  33. Z. Eslami-S, K. Majidzadeh-A, S. Halvaei, F. Babapirali, R. Esmaeili, Microbiome and breast cancer: new role for an ancient population. Front. Oncol. 10, 120 (2020). https://doi.org/10.3389/fonc.2020.00120
  34. K.B. Low, M. Ittensohn, T. Le, J. Platt, S. Sodi et al., Lipid a mutant salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat. Biotechnol. 17, 37–41 (1999). https://doi.org/10.1038/5205
  35. L.A. Diaz Jr., I. Cheong, C.A. Foss, X. Zhang et al., Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol. Sci. 88, 562–575 (2005). https://doi.org/10.1093/toxsci/kfi316
  36. M. Shinnoh, M. Horinaka, T. Yasuda, S. Yoshikawa, M. Morita et al., Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8. Int. J. Oncol. 42, 903–911 (2013). https://doi.org/10.3892/ijo.2013.1790
  37. D.T. Le, T.W. Dubenksy Jr., D.G. Brockstedt, Clinical development of listeria monocytogenes-based immunotherapies. Semin. Oncol. 39, 311–322 (2012). https://doi.org/10.1053/j.seminoncol.2012.02.008
  38. O. Felfoul, M. Mohammadi, S. Taherkhani, D. de Lanauze, Y.Z. Xu et al., Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nat. Nanotechnol. 11, 941–947 (2016). https://doi.org/10.1038/nnano.2016.137
  39. S. Xie, L. Zhao, X. Song, M. Tang, C. Mo et al., Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. J. Control. Release 268, 390–399 (2017). https://doi.org/10.1016/j.jconrel.2017.10.041
  40. J. Stritzker, S. Weibel, P. Hill, T. Oelschlaeger, W. Goebel et al., Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. IJMM 297, 151–162 (2007). https://doi.org/10.1016/j.ijmm.2007.01.008
  41. S. Xie, M. Chen, X. Song, Z. Zhang, Z. Zhang et al., Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy. Acta Biomater. 78, 198–210 (2018). https://doi.org/10.1016/j.actbio.2018.07.041
  42. P.A. de Boer, R.E. Crossley, L.I. Rothfield, A division inhibitor and a topological specificity factor coded for by the minicell locus determine proper placement of the division septum in E. coli. Cell 56, 641–649 (1989). https://doi.org/10.1016/0092-8674(89)90586-2
  43. J.A. MacDiarmid, J. Madrid-Weiss, N.B. Amaro-Mugridge, L. Phillips, H. Brahmbhatt, Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors. Cell Cycle 6, 2099–2105 (2007). https://doi.org/10.4161/cc.6.17.4648
  44. K. Matsuo, V.K. Bond, M.L. Eno, D.D. Im, N.B. Rosenshein, Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int. J. Cancer 125, 2721–2727 (2009). https://doi.org/10.1002/ijc.24654
  45. J.A. MacDiarmid, N.B. Amaro-Mugridge, J. Madrid-Weiss, I. Sedliarou, S. Wetzel et al., Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 27, 643–651 (2009). https://doi.org/10.1038/nbt.1547
  46. S. Felgner, D. Kocijancic, M. Frahm, R. Curtiss, M. Erhardt et al., Optimizing Salmonella enterica serovar typhimurium for bacteria-mediated tumor therapy. Gut Microbes 7, 171–177 (2016). https://doi.org/10.1080/19490976.2016.1155021
  47. J. Nam, S. Son, L.J. Ochyl, R. Kuai, A. Schwendeman et al., Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat. Commun. 9, 1074 (2018). https://doi.org/10.1038/s41467-018-03473-9
  48. F. Chen, Z. Zang, Z. Chen, L. Cui, Z. Chang et al., Nanophotosensitizer-engineered salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials 214, 119226 (2019). https://doi.org/10.1016/j.biomaterials.2019.119226
  49. W. Chen, Y. Wang, M. Qin, X. Zhang, Z. Zhang et al., Bacteria-driven hypoxia targeting for combined biotherapy and photothermal therapy. ACS Nano 12, 5995–6005 (2018). https://doi.org/10.1021/acsnano.8b02235
  50. J. Huang, L. Lin, D. Sun, H. Chen, D. Yang et al., Cheminform abstract: bio-inspired synthesis of metal nanomaterials and applications. ChemInform (2015). https://doi.org/10.1002/chin.201541232
  51. Q.-W. Chen, X.-H. Liu, J.-X. Fan, S.-Y. Peng, J.-W. Wang et al., Self-mineralized photothermal bacteria hybridizing with mitochondria-targeted metal–organic frameworks for augmenting photothermal tumor therapy. Adv. Funct. Mater. 30, 1909806 (2020). https://doi.org/10.1002/adfm.201909806
  52. C.H. Luo, C.T. Huang, C.H. Su, C.S. Yeh, Bacteria-mediated hypoxia-specific delivery of nanoparticles for tumors imaging and therapy. Nano Lett. 16, 3493–3499 (2016). https://doi.org/10.1021/acs.nanolett.6b00262
  53. V. Gujrati, J. Prakash, J. Malekzadeh-Najafabadi, A. Stiel, U. Klemm et al., Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging. Nat. Commun. 10, 1114 (2019). https://doi.org/10.1038/s41467-019-09034-y
  54. Y. Ye, C. Wang, X. Zhang, Q. Hu, Y. Zhang et al., A melanin-mediated cancer immunotherapy patch. Sci. Immunol. (2017). https://doi.org/10.1126/sciimmunol.aan5692
  55. Q. Chen, G. Huang, W. Wu, J. Wang, J. Hu et al., A hybrid eukaryotic-prokaryotic nanoplatform with photothermal modality for enhanced antitumor vaccination. Adv. Mater. 32, e1908185 (2020). https://doi.org/10.1002/adma.201908185
  56. E. Kolaczkowska, P. Kubes, Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159–175 (2013). https://doi.org/10.1038/nri3399
  57. J. Nicolás-Ávila, J.M. Adrover, A. Hidalgo, Neutrophils in homeostasis, immunity, and cancer. Immunity 46, 15–28 (2017). https://doi.org/10.1016/j.immuni.2016.12.012
  58. M. Li, S. Li, H. Zhou, X. Tang, Y. Wu et al., Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy. Nat. Commun. 11, 1126 (2020). https://doi.org/10.1038/s41467-020-14963-0
  59. B. Sun, C. Luo, X. Zhang, M. Guo, M. Sun et al., Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy. Nat. Commun. 10, 3211 (2019). https://doi.org/10.1038/s41467-019-11193-x
  60. C. Luo, J. Sun, D. Liu, B. Sun, L. Miao et al., Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 16, 5401–5408 (2016). https://doi.org/10.1021/acs.nanolett.6b01632
  61. S. Mijatović, A. Savić-Radojević, M. Plješa-Ercegovac, T. Simić, F. Nicoletti et al., The double-faced role of nitric oxide and reactive oxygen species in solid tumors. Antioxidants 9, 374 (2020). https://doi.org/10.3390/antiox9050374
  62. D.W. Zheng, Y. Chen, Z.H. Li, L. Xu, C.X. Li et al., Optically-controlled bacterial metabolite for cancer therapy. Nat. Commun. 9, 1680 (2018). https://doi.org/10.1038/s41467-018-03233-9
  63. J.-X. Fan, M.-Y. Peng, H. Wang, H.-R. Zheng, Z.-L. Liu et al., Biomedical materials: engineered bacterial bioreactor for tumor therapy via fenton-like reaction with localized H2O2 generation. Adv. Mater. 31, 1970119 (2019). https://doi.org/10.1002/adma.201970119
  64. L. Feng, L. Cheng, Z. Dong, D. Tao, T.E. Barnhart et al., Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy. ACS Nano 11, 927–937 (2017). https://doi.org/10.1021/acsnano.6b07525
  65. L. Liu, H. He, Z. Luo, H. Zhou, R. Liang et al., In situ photocatalyzed oxygen generation with photosynthetic bacteria to enable robust immunogenic photodynamic therapy in triple-negative breast cancer. Adv. Funct. Mater. 30, 1910176 (2020). https://doi.org/10.1002/adfm.201910176
  66. M. Wu, W. Wu, Y. Duan, X. Li, G. Qi et al., Photosensitizer-bacteria biohybrids promote photodynamic cancer cell ablation and intracellular protein delivery. Chem. Mater. 31, 7212–7220 (2019). https://doi.org/10.1021/acs.chemmater.9b01518
  67. C. Stern, N. Kasnitz, D. Kocijancic, S. Trittel, P. Riese et al., Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy. Int. J. Cancer 137, 2019–2028 (2015). https://doi.org/10.1002/ijc.29567
  68. J.H. Zheng, V.H. Nguyen, S.N. Jiang, S.H. Park, W. Tan et al., Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci. Transl. Med. (2017). https://doi.org/10.1126/scitranslmed.aak9537
  69. C. Gurbatri, I. Lia, R. Vincent, C. Coker, S. Castro et al., Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. (2020). https://doi.org/10.1126/scitranslmed.aax0876
  70. O.Y. Kim, H.T. Park, N.T.H. Dinh, S.J. Choi, J. Lee et al., Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat. Commun. 8, 626 (2017). https://doi.org/10.1038/s41467-017-00729-8
  71. R.B. Patel, M. Ye, P.M. Carlson, A. Jaquish, L. Zangl et al., Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles. Adv. Mater. 31, e1902626 (2019). https://doi.org/10.1002/adma.201902626
  72. Q. Chen, H. Bai, W. Wu, G. Huang, Y. Li et al., Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention. Nano Lett. 20, 11–21 (2020). https://doi.org/10.1021/acs.nanolett.9b02182
  73. W. Chen, Z. Guo, Y. Zhu, N. Qiao, Z. Zhang et al., Combination of bacterial-photothermal therapy with an anti-pd-1 peptide depot for enhanced immunity against advanced cancer. Adv. Funct. Mater. 30, 1906623 (2020). https://doi.org/10.1002/adfm.201906623
  74. P. Lehouritis, C. Springer, M. Tangney, Bacterial-directed enzyme prodrug therapy. J. Control. Release 170, 120–131 (2013). https://doi.org/10.1016/j.jconrel.2013.05.005
  75. P. Lehouritis, G. Hogan, M. Tangney, Designer bacteria as intratumoural enzyme biofactories. Adv. Drug Deliv. Rev. 118, 8–23 (2017). https://doi.org/10.1016/j.addr.2017.09.012
  76. P. Lehouritis, M. Stanton, F.O. McCarthy, M. Jeavons, M. Tangney, Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria. J. Control. Release 222, 9–17 (2016). https://doi.org/10.1016/j.jconrel.2015.11.030
  77. C.M. Cheng, F.M. Chen, Y.L. Lu, S.C. Tzou, J.Y. Wang et al., Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs. Cancer Gene Ther. 20, 276–281 (2013). https://doi.org/10.1038/cgt.2013.17
  78. J.V.E. Chan-Hyams, D.F. Ackerley, Protocol for evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model gram negative bacterial vector. MethodsX 7, 100797 (2020). https://doi.org/10.1016/j.mex.2020.100797
  79. B. Wei, P.P. Wang, Z.X. Yan, R. Yan, Characteristics and molecular determinants of a highly selective and efficient glycyrrhizin-hydrolyzing β-glucuronidase from Staphylococcus pasteuri 3I10. Appl. Microbiol. Biotechnol. 102, 9193–9205 (2018). https://doi.org/10.1007/s00253-018-9285-x
  80. A. Afkhami-Poostchi, M. Mashreghi, M. Iranshahi, M. Matin, Use of a genetically engineered E. coli overexpressing β-glucuronidase accompanied by glycyrrhizic acid, a natural and anti-inflammatory agent, for directed treatment of colon carcinoma in a mouse model. Int. J. Pharm. 579, 119159 (2020). https://doi.org/10.1016/j.ijpharm.2020.119159
  81. S. Bochum, S. Berger, U.M. Martens, Olaparib. Recent Results Cancer Res. 211, 217–233 (2018). https://doi.org/10.1007/978-3-319-91442-8_15
  82. Y. Shi, W. Zheng, K. Yang, K.G. Harris, K. Ni et al., Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J. Exp. Med. (2020). https://doi.org/10.1084/jem.20192282
  83. A.C. Anselmo, K.J. McHugh, J. Webster, R. Langer, A. Jaklenec, Layer-by-layer encapsulation of probiotics for delivery to the microbiome. Adv. Mater. 28, 9486–9490 (2016). https://doi.org/10.1002/adma.201603270
  84. Z. Cao, X. Wang, Y. Pang, S. Cheng, J. Liu, Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment. Nat. Commun. 10, 5783 (2019). https://doi.org/10.1038/s41467-019-13727-9
  85. Z. Cao, S. Cheng, X. Wang, Y. Pang, J. Liu, Camouflaging bacteria by wrapping with cell membranes. Nat. Commun. 10, 3452 (2019). https://doi.org/10.1038/s41467-019-11390-8
  86. B. Mostaghaci, O. Yasa, J. Zhuang, M. Sitti, Bioadhesive bacterial microswimmers for targeted drug delivery in the urinary and gastrointestinal tracts. Adv. Sci. 4, 1700058 (2017). https://doi.org/10.1002/advs.201700058
  87. J.X. Fan, Z.H. Li, X.H. Liu, D.W. Zheng, Y. Chen et al., Bacteria-mediated tumor therapy utilizing photothermally-controlled tnf-α expression via oral administration. Nano Lett. 18, 2373–2380 (2018). https://doi.org/10.1021/acs.nanolett.7b05323
  88. Q. Song, C. Zheng, J. Jia, H. Zhao, Q. Feng et al., A probiotic spore-based oral autonomous nanoparticles generator for cancer therapy. Adv. Mater. 31, 1903793 (2019). https://doi.org/10.1002/adma.201903793
  89. T. Ren, J. Gou, W. Sun, X. Tao, X. Tan et al., Entrapping of nanoparticles in yeast cell wall microparticles for macrophage-targeted oral delivery of cabazitaxel. Mol. Pharm. 15, 2870–2882 (2018). https://doi.org/10.1021/acs.molpharmaceut.8b00357
  90. X. Zhou, X. Zhang, S. Han, Y. Dou, M. Liu et al., Yeast microcapsule-mediated targeted delivery of diverse nanoparticles for imaging and therapy via the oral route. Nano Lett. 17, 1056–1064 (2017). https://doi.org/10.1021/acs.nanolett.6b04523
  91. L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent et al., Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015). https://doi.org/10.3322/caac.21262
  92. M. Zhang, M. Li, L. Du, J. Zeng, T. Yao et al., Paclitaxel-in-liposome-in-bacteria for inhalation treatment of primary lung cancer. Int. J. Pharm. 578, 119177 (2020). https://doi.org/10.1016/j.ijpharm.2020.119177
  93. L. Peng, M. Wang, Y. Chu, L. Zhang, J. Niu et al., Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-trail-programmed therapy against melanoma. Sci. Adv. 6, eaba2735 (2020). https://doi.org/10.1126/sciadv.aba2735
  94. M. Prausnitz, R. Langer, Transdermal drug delivery. Nat. Biotechnol. 26, 1261–1268 (2008). https://doi.org/10.1038/nbt.1504
  95. L. Yepes-Molina, M.C. Martínez-Ballesta, M. Carvajal, Plant plasma membrane vesicles interaction with keratinocytes reveals their potential as carriers. J. Adv. Res. 23, 101–111 (2020). https://doi.org/10.1016/j.jare.2020.02.004
  96. F. Martinez-Morales, A. Borges, A. Martinez, K. Shanmugam, L. Ingram, Chromosomal integration of heterologous DNA in Escherichia coli with precise removal of markers and replicons used during construction. J. Bacteriol. 181, 7143–7148 (1999). https://doi.org/10.1128/jb.181.22.7143-7148.1999
Read More
Author biographies are not available.
Download this PDF file
PDF
Statistic
Read Counter : 50539 Download : 38430